NASDAQ:VBLT

Vascular Biogenics Stock Forecast, Price & News

$2.06
+0.03 (+1.48 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.03
$2.12
50-Day Range
$1.69
$2.26
52-Week Range
$1.01
$3.17
Volume268,537 shs
Average Volume954,618 shs
Market Capitalization$99.27 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17
30 days | 90 days | 365 days | Advanced Chart
Receive VBLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VBLT
Previous SymbolNASDAQ:VBLX
CUSIPN/A
Phone972-8993-5000
Employees38
Year FoundedN/A

Sales & Book Value

Annual Sales$560,000.00
Book Value$1.00 per share

Profitability

Net Income$-19,460,000.00
Net Margins-2,692.41%

Debt

Price-To-Earnings

Miscellaneous

Market Cap$99.27 million
Next Earnings Date5/11/2021 (Confirmed)
OptionableOptionable

Headlines

See More Headlines
Vascular Biogenics logo

About Vascular Biogenics

Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; and VB-703 for NASH and renal fibrosis. In addition, the company is developing VB-201, a Lecinoxoid-based product candidate to treat atherosclerosis that has completed Phase II clinical; and is in Phase II exploratory trials for COVID-19, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

MarketRank

Overall MarketRank

1.31 out of 5 stars

Medical Sector

813th out of 2,042 stocks

Pharmaceutical Preparations Industry

384th out of 770 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions

Is Vascular Biogenics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Vascular Biogenics stock.
View analyst ratings for Vascular Biogenics
or view top-rated stocks.

What stocks does MarketBeat like better than Vascular Biogenics?

Wall Street analysts have given Vascular Biogenics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vascular Biogenics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Vascular Biogenics' next earnings date?

Vascular Biogenics is scheduled to release its next quarterly earnings announcement on Tuesday, May 11th 2021.
View our earnings forecast for Vascular Biogenics
.

How can I listen to Vascular Biogenics' earnings call?

Vascular Biogenics will be holding an earnings conference call on Tuesday, May 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) released its quarterly earnings data on Wednesday, March, 24th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.01. The biopharmaceutical company earned $0.21 million during the quarter, compared to the consensus estimate of $0.20 million. Vascular Biogenics had a negative trailing twelve-month return on equity of 61.77% and a negative net margin of 2,692.41%.
View Vascular Biogenics' earnings history
.

How has Vascular Biogenics' stock been impacted by Coronavirus (COVID-19)?

Vascular Biogenics' stock was trading at $1.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VBLT stock has increased by 68.9% and is now trading at $2.06.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for VBLT?

4 brokers have issued 1 year price objectives for Vascular Biogenics' shares. Their forecasts range from $2.50 to $5.00. On average, they expect Vascular Biogenics' share price to reach $4.13 in the next year. This suggests a possible upside of 100.2% from the stock's current price.
View analysts' price targets for Vascular Biogenics
or view top-rated stocks among Wall Street analysts.

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the following people:
  • Prof. Dror Harats, CEO & Director (Age 64)
  • Mr. Amos Ron, CFO & Company Sec. (Age 66)
  • Dr. Erez Feige, VP of Bus. Operations (Age 47)
  • Dr. Eyal Breitbart, VP of Research & Operations (Age 54)
  • Dr. Naamit Sher, VP of Drug Devel. & Regulatory Affairs (Age 67)
  • Advocate Ayelet Horn, Gen. Counsel (Age 50)
  • Deborah Scott, Managing Director of Financial Communications
  • Dr. Yael Cohen, Medical Director (Age 58)

Who are some of Vascular Biogenics' key competitors?

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

How do I buy shares of Vascular Biogenics?

Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $2.06.

How much money does Vascular Biogenics make?

Vascular Biogenics has a market capitalization of $99.27 million and generates $560,000.00 in revenue each year. The biopharmaceutical company earns $-19,460,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

How many employees does Vascular Biogenics have?

Vascular Biogenics employs 38 workers across the globe.

What is Vascular Biogenics' official website?

The official website for Vascular Biogenics is www.vblrx.com.

Where are Vascular Biogenics' headquarters?

Vascular Biogenics is headquartered at 8 HASATAT STREET, MODI IN L3, 7178106.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at 972-8993-5000 or via email at [email protected]


This page was last updated on 5/9/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.